Routine board refresh with no financial or operational catalyst. Monitor upcoming clinical trial initiation for IBIO-610/IBIO-600 as the next potential value inflection point.
Price Chart
Executive Summary
iBio appointed Dr. Elizabeth Stoner to its Board of Directors, replacing Evert Schimmelpennink who resigned. Dr. Stoner brings extensive biotech R&D and clinical development experience as the company prepares for its first human clinical trial. This is a routine board refresh with no material financial impact.
Key Facts
- Dr. Elizabeth Stoner appointed as Class II director and Compensation Committee member effective May 7, 2026
- Evert Schimmelpennink resigned from the Board effective immediately, not due to any disagreement with the company
- Dr. Stoner will receive standard non-employee director compensation: $40,000 annual board fee, $7,500 annual committee fee, and eligibility for equity awards
- Dr. Stoner is an Entrepreneur Partner at MPM BioImpact with 35+ years of biotech experience including roles at Merck Research Laboratories and Rhythm Pharmaceuticals
- Company is preparing for its first human clinical trial for IBIO-610 and IBIO-600 assets
Financial Impact
Standard director compensation of $40,000 annual board fee plus $7,500 committee fee — immaterial relative to company's $57M market cap
Risk Factors
- No clinical data milestones announced — stock remains pre-revenue with binary trial risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-057945 |
| Document: ibio-20260507xex99d1.htm | 0001104659-26-057945 |
| Document: 0001104659-26-057945-index-headers.html | 0001104659-26-057945 |
| Document: 0001104659-26-057945-index.html | 0001104659-26-057945 |
| Document: 0001104659-26-057945.txt | 0001104659-26-057945 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8210 | awaiting T+5 | — | $0.7100 (−13.52%) |
Oct 14, 2026 12d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7100 (−9.07%) |
Oct 13, 2026 13d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7100 (−9.18%) |
Sep 14, 2026 6w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7100 (−40.34%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7100 (−47.79%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7100 (−47.79%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7100 (−59.43%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7100 (−51.70%) |
May 12, 2026 23w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7100 (+54.19%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7100 (−57.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers